

PERSONAL INFORMATION

Valentina - Oana Buda



 Timisoara (Romania)



 buda.valentina.oana@gmail.com; buda.valentina@umft.ro

WORK EXPERIENCE

01/05/2023 - present

Membru al Comitetului de Educație din cadrul Societății Europene a Farmaciștilor clinicieni (ESCP)

Coordonarea activităților educaționale în cadrul societății (de la organizarea webinarilor, la dezvoltarea programelor științifice/selecția temelor de discuție în cadrul evenimentelor ESCP)

20/09/2021 - prezent

Conferentiar universitar

Universitatea de Medicina si Farmacie "Victor Babes", Timisoara (Romania)
Facultatea de Farmacie

Disciplina de Farmacie clinica - Asistenta farmaceutica – Comunicare in farmacie

Cursuri si lucrari practice de Farmacie clinica , Asistenta farmaceutica si Comunicare in farmacie cu studentii anului V de la sectia romana si franceza ai Fac de Farmacie, precum si cu studentii anul III ai sectie de Asistenta de farmacie - Lugoj.

14/02/2021 - 19/09/2021

Conferentiar universitar

Universitatea de Medicina si Farmacie "Victor Babes", Timisoara (Romania)
Facultatea de Farmacie

Disciplina de Chimie farmaceutică - Farmacologie - Farmacie clinica - Asistenta farmaceutica

Cursuri si lucrari practice de Asistenta farmaceutica si Comunicare in farmacie cu studentii anului V de la sectia romana si franceza ai Fac de Farmacie

01/09/2020 – 14/02/2021

Sef Lucrari

Universitatea de Medicina si Farmacie "Victor Babes", Timisoara (Romania)
Facultatea de Farmacie

Disciplina de Farmacologie - Farmacie clinica - Asistenta farmaceutica

Cursuri si lucrari practice de Farmacie clinica cu studentii anului V de la sectia romana si franceza ai Fac de Farmacie. Lucrări practice de Farmacologie - Farmacoterapie cu studentii anului III, IV de la sectia romana si franceza ai Fac de Farmacie

01/09/2017–31/08/2020

Asistent universitar - perioada nedeterminata

Universitatea de Medicina si Farmacie "Victor Babes", Timisoara (Romania)
Facultatea de Farmacie

Disciplina de Farmacologie - Farmacie clinica - Asistenta farmaceutica

Lucrari practice de Farmacologie si Farmacie clinica cu studentii anului III, IV si V de la sectia romana

si franceza ai Fac de Farmacie

- 01/10/2013–31/08/2017 **Asistent universitar - perioada determinata**
Universitatea de Medicina si Farmacie "Victor Babes" - Facultatea de farmacie, Timisoara (România)
Disciplina de Farmacologie și Farmacie clinică - Sustinerea de laboratoare (lucrari practice) de Farmacologie si Farmacie clinică in limba romana si in limba franceza
- 01/01/2013–31/12/2015 **Rezident - Farmacie clinica**
Spitalul Clinic Municipal de Urgenta, Timisoara (România)
- 15/04/2012–01/07/2012 **Preparator - plata cu ora**
Universitatea de vest "Vasile Goldis - Facultatea de Medicina, Farmacie si Medicina dentara, Arad (România)
Disciplina de Farmacologie – cursuri si laboratoare de Farmacologie in limba Ro, Fr, En
- 01/10/2010–01/07/2013 **Preparator - plata cu ora**
Universitatea de Medicina si Farmacie "Victor Babes" Timisoara, Timisoara (România)
Disciplina de Farmacologie si Farmacie clinica - din cadrul Facultatii de Farmacie - sustinerea de laboratoare (lucrari practice) cu studentii sectiei Ro si Fr
- 16/11/2010–01/03/2012 **Farmacist diriginte**
SC Catena Hygeia SRL, Timisoara (România)
Aprovizionare, gestiune, rapoarte contabile zilnice, coordonarea activitatilor din farmacie, impartirea de sarcini personalului, relatii CJAS - farmacie, campanii publicitare
- 01/07/2005–01/10/2010 **Operator PC**
Farmacie
Receptie marfa
Stocuri
Gestiune
Aprovizionare

EDUCATION AND TRAINING

- 06/12/2023 **Suținere teză abilitare**
IOSUD/IOD Universitatea de Medicină și Farmacie "Victor Babeș" din Timișoara. Abilitare in Domeniul Medicină.
Titlul tezei: Optimizarea farmacoterapiei și noi abordări farmacologice în patologii cu componentă inflamatorie.
Ordin Min. Ed.: 3886/28.02.2024
- 01/01/2022 – 26/02/2022 **Curs online organizat de către Organizația Mondială a Sănătății - Antimicrobial Stewardship: A competency-based approach**
World Health Organization

Curs on-line HARVAD MEDICAL SCHOOL

- 01/05/2021 – 30/06/2021 Immunology – Novel therapies for chronic inflammation
Pharmacology - Essentials
- 20/01/2020-31/01/2020 **Stagiu de Medicina Personalizata**
Erasmus University Medical Center, Rotterdam, Olanda
- Stagii clinice pe secțiile Spitalului universitar.
- Participarea la discutii cu echipa medicala în vederea gasirii unor solutii terapeutice cat mai eficiente si personalizate, pentru pacientii la care tratamentul clasic nu a avut nicio eficacitate.
- Participarea la discutii de farmacogenomica, semiologie medicala, manipularea informatiilor obtinute din secventionalizarea genomului uman cu ajutorul unor programe informatizate
- Sub coordonarea prof. dr. Peter J. van der Spek, Departamentul de BioInformatica Medicala
- 01/03/2017–10/06/2017 **Stagiu de Farmacie clinica**
Universite Catholique de Louvain, Bruxelles (Belgium)
- Stagii clinice pe sectia de geriatrie in special, dar si pe sectiile de: boli infectioase, oncologie.
- Cursuri in cadrul Fac de Farmacie - audiate, precum si alte cursuri de educatie continua
- Participarea la sustinerea si expunerea seminarilor de farmacoterapie pentru studentii Fac de Farmacie
- Participarea si implicarea in proiectele locale derulate in cadru Fac (proiecte de licenta, masterat, educatie continua a farmacistilor, doctorat, studii clinice)
- Sub coordonarea: Anne Spinewine, Olivia Dalleur, Paul Tulkens
- 01/10/2011–27/10/2016 **Doctorat**
Universitatea de Medicina si Farmacie "Victor Babes", Timisoara (România)
- Doctorat in Medicina - conducator prof. dr. Mirela Cleopatra Tomescu, UMFTVB
- Titlu: Efectele perindoprilului si candesartanului asupra endotelului vascular la pacienti hipertensivi, apreciate prin pentraxina-3, endoglina si trombospondina-1.
- Ordin Min. Ed.: 3769/20.04.2017
- 01/01/2013–31/12/2015 **Rezidentiat - Farmacie clinica**
Universitatea de Medicina si Farmacie "Victor Babes", Timisoara (România)
- 01/10/2012–20/07/2013 **Masterat - Managementul farmacoterapiei la persoanele varstnice**
Universitatea de Medicina si Farmacie "Victor Babes", Timisoara (România)
- 01/10/2010–01/07/2012 **Masterat biostatistica medicala**
Universitatea Bucuresti, Bucuresti (România)
- 01/10/2005–01/10/2010 **Farmacist**
Universitatea de Medicina si Farmacie "Victor Babes" - Facutatea de farmacie, Timisoara (România)
- 01/09/2001–01/06/2005 **Absolventa Bacalaureat**

Grupul Scolar Industrial "Mihai Viteazul", Ineu (România)

PERSONAL SKILLS

Mother tongue(s) română

Foreign language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
engleză	C1	C1	C1	C1	C1
Certificat FCE Cambridge 2010					
franceză	C1	C1	C1	C1	C1
Certificat DALF 2018					
spaniolă	A2	A2	A2	A2	A2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

Communication skills Voluntariat - campanii umanitare, electorale
 Organizare si participare la congrese studentesti locale, nationale, internationale
 Spirit de echipa, comunicativa, perseverenta, responsabila, organizata, sociabila

Organisational / managerial skills Farmacist sef - 2010 – 2012

Director de proiect tineri cercetatori - PII-C4-TC-2016/16441-09 - Rolul perindoprilului si al candesartanului in disfunctia endoteliala la pacientii hipertensivi – perioada de desfasurare: 2015 – 2016. Finantat de: UMF Victor Babes, Timisoara. Durata finantare: 12 luni. Suma finantata: 5 000 euro

Director de proiect – 5DOC/1425/03.02.2020 – A comprehensive *in vitro* and *in vivo* evaluation of *Aronia melanocarpa* (Michx.) Elliot standardized bio juice on blood pressure levels and endothelial damage. A prospective study. Finantat de: UMF Victor Babes, Timisoara. Durata finantare: 36 luni. Suma finantata: 25 000 euro

Job-related skills Permis de conducere categoria B

Membru in urmatoarele proiecte:

- 3POSTDOC/1238/30.01.2020 – *Populi gemmae* – a double gain for the pharmaceutical field: therapeutic potential and bio-source for green synthesis of silver nanoparticles. Finantat de: UMF Victor Babes, Timisoara. Durata finantare: 36 luni. Suma finantata: 30 000 euro. Director de proiect: Corina Danciu
- PN-III-P1-1.1.-TE-2016-1165 – Tehnici instrumentale hifenate si complementare de analiza, control si recuperare a compusilor bioactivi utilizati in terapii hormonale. Finantat de: UEFISCDI. Durata finantare: 24 luni. Suma finantata: 450 000 RON. Director de proiect: Ionut Ledeti

Reviewer (referent stiintific) pentru:

- > 60 articole in reviste ISI (cu factor de impact 1 – 9) si
- > 15 articole in reviste indexate in Pubmed si in baze de date internationale.

Coordonator a 30 lucrari de licenta (inclusiv anul univ 2022/2023) in cadrul UMFVBT.

Lucrari stiintifice premiate la nivel national : 28 (Premii UEFISCDI, PRESCI 2017, 2019, 2020, 2021, 2022, 2023)

Premiul special – Conferinta Nationala de Farmacie clinica, ed. I, Bucuresti, 17 – 18 iunie 2016

Digital skills

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem solving
Proficient user	Independent user	Independent user	Independent user	Independent user

Digital skills - Self-assessment grid

Microsoft Office
Pharmec - program gestiune farmacie

Other skills Lista publicatiilor stiintifice:

- 1) Romanescu M, Oprean C, Lombrea A, Badescu B, Teodor A, Constantin GD, Andor M, Folescu R, Muntean D, Danciu C, Dalleur O, Batrina SL, Cretu O, **Buda VO**. Current State of Knowledge Regarding WHO High Priority Pathogens—Resistance Mechanisms and Proposed Solutions through Candidates Such as Essential Oils: A Systematic Review. *International Journal of Molecular Sciences*. 2023; 24(11):9727. <https://doi.org/10.3390/ijms24119727> **ISI, impact factor 5.6/2022**
- 2) Lombrea A, Romanescu M, Jianu N, Andor M, Suci M, Man DE, Danciu C, Dehelean CA, **Buda V**. Sex-Related Differences in the Pharmacological Response in SARS-CoV-2 Infection, Dyslipidemia, and Diabetes Mellitus: A Narrative Review. *Pharmaceuticals*. 2023; 16(6):853. <https://doi.org/10.3390/ph16060853> **ISI, impact factor 4.6/2022**
- 3) Badescu B, **Buda V***, Romanescu M, Lombrea A, Danciu C, Dalleur O, Dohou AM, Dumitrascu V, Cretu O, Licker M, Muntean D. Current State of Knowledge Regarding WHO Critical Priority Pathogens: Mechanisms of Resistance and Proposed Solutions through Candidates Such as Essential Oils. *Plants (Basel)*. 2022 Jul 6;11(14):1789. doi: 10.3390/plants11141789. **ISI, impact factor 4.50/2022**
- 4) Romanescu M, **Buda V***, Lombrea A, Andor M, Ledeti I, Suci M, Danciu C, Dehelean CA, Dehelean L. Sex-Related Differences in Pharmacological Response to CNS Drugs: A Narrative Review. *Journal of Personalized Medicine*. 2022; 12(6):907. <https://doi.org/10.3390/jpm12060907> **ISI, impact factor 3.5/2022**
- 5) **Buda V**, Prelipcean A, Cozma D, Man DE, Negres S, Scurtu A, Suci M, Andor M, Danciu C, Crisan S, Dehelean CA, Petrescu L, Rachieru C. An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure. *J Clin Med*. 2022;11(7):2020. doi: 10.3390/jcm11072020. **ISI, impact factor 3.9/2022**
- 6) **Buda V**, Prelipcean A, Cristescu C, Roja A, Dalleur O, Andor M, Danciu C, Ledeti A, Dehelean CA, Cretu O. Prescription Habits Related to Chronic Pathologies of Elderly People in Primary Care in the Western Part of Romania: Current Practices, International Recommendations, and Future Perspectives Regarding the Overuse and Misuse of Medicines. *Int J Environ Res Public Health*. 2021 Jul 1;18(13):7043. doi: 10.3390/ijerph18137043. **ISI, impact factor 4.614/2021**
- 7) **Buda V**, Brezoiu AM, Berger D, Pavel IZ, Muntean D, Minda D, Dehelean CA, Soica C, Diaconeasa Z, Folescu R, Danciu C. Biological Evaluation of Black Chokeberry Extract Free and Embedded in Two Mesoporous Silica-Type Matrices. *Pharmaceutics*. 2020 Sep 1;12(9):838. doi: 10.3390/pharmaceutics12090838. **ISI, impact factor 6.321/2020**
- 8) **Buda V**, Prelipcean A, Andor M, et al. Potentially Inappropriate Prescriptions in Ambulatory Elderly Patients Living in Rural Areas of Romania Using STOPP/START (Version 2) Criteria. *Clin Interv Aging*. 2020; 15:407-417. doi:10.2147/CIA.S233270 **ISI, impact factor 4.458/2020**
- 9) **Buda V**, Baul B, Andor M, et al. Solid State Stability and Kinetics of Degradation for Candesartan-Pure Compound and Pharmaceutical Formulation. *Pharmaceutics*. 2020;12(2):86. doi:10.3390/pharmaceutics12020086 **ISI, impact factor 6.321/2020**

10) Radu G, Luca C, Petrescu L, Bordejevic DA, Tomescu MC, Andor M, Citu I, Mavrea A, **Buda V** et al. The Predictive Value of Endothelial Inflammatory Markers in the Onset of Schizophrenia. *Neuropsychiatr Dis Treat*. 2020;16:545-555. doi:10.2147/NDT.S240349. **ISI, impact factor 2.570/2020 (coresp author)**

11) **Buda V**, Andor M, Baibata DE, Cozlac R, Radu G, Coricovac D, Danciu C, Ledeti I, Cheveresan A, Nica C, Tuduce P, Tomescu MC. Decreased sEng plasma levels in hypertensive patients with endothelial dysfunction under chronic treatment with Perindopril. *Drug Design Development and Therapy*. 2019; 13:1915-1924. **ISI, impact factor: 3.216/2019.**

12) Muntean D, Licker M, Alexa E, POpescu I, Jianu C, **Buda V***, Dehelean CA, Ghiulai R, Horhat F, Horhat D, Danciu C. Evaluation of essential oil obtained from *Mentha x piperita* L. against multidrug-resistant strains. *Infection and Drug Resistance*. 2019; 12:2905-2914. **ISI, factor de impact 2.984/2019**

13) Suciu M, Suciu L, Vlaia L, Voicu M, **Buda V**, Dragan L, Andor M, Vlaia V, Cristescu C. Prevalence and the patterns of the use of non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol among the general population. *Revista Farmacia*. 2019; 67(2):337-345. **ISI, factor de impact 1.607/2019**

14) Andor M, Dehelean L, Romosan AM, **Buda V**, Radu G, Caruntu F, Bordejevic A, Manea MM, Papava I, Bredicean CA, Romosan RS, Tomescu M. A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication. *Neuropsychiatric Disease and Treatment*. 2019; 15:349-355. **ISI, factor de impact 2.157/2019**

15) **Buda V**, Andor M, Petrescu L, Cristescu C, Baibata DE, Voicu M, Munteanu M, Citu I, Munteanu C, Cretu O, Tomescu MC. Perindopril Induces TSP-1 Expression in Hypertensive Patients with Endothelial Dysfunction in Chronic Treatment. *Int J Mol Sci*. 2017; 18(2). doi: 10.3390/ijms18020348. **ISI, factor de impact 3.687/2017**

16) **Buda V**, Andor M, Ledeti A, Ledeti I, Vlase G, Vlase T, Cristescu C, Voicu M, Suciu L, Tomescu MC. Comparative Solid-State Stability of Perindopril Active Substance vs. Pharmaceutical Formulation. *Int J Mol Sci*. 2017; 15;18(1). doi: 10.3390/ijms18010164. **ISI, factor de impact 3.687/2017**

17) **Buda V**, Andor M, Cristescu C, Voicu M, Cochera F, Tuduce P, Petrescu L, Tomescu MC. The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension. *Ir J Med Sci*. 2017; 186(3):621-629. doi: 10.1007/s11845-017-1580-5. **ISI, factor de impact 1.045/2017**

ISI abstracts

Buda V, Prelipcean A, Dalleur O, Suciu M, Suciu L, Buda S, Romanescu M, Mailat D, Mateoc T, Dohou A, Cristescu C, Petrescu L, Cretu O, Andor M. Underuse of Medicines in Romanian Elderly Population based on START v.2, 2015 Criteria. *Metabolism: Clinical and Experimental*. 2023; 142:155505 doi: 10.1016/j.metabol.2023.155505 **ISI, impact factor 9.8/2022**

Buda VO, Bina AM, Minda D, Danciu C, Dehelean CA, Muntean DM, Sturza A. Assessment of dose-dependent vasculoprotective effects of aronia extracts in mice aorta. *Journal of Molecular and Cellular Cardiology*. 2022; 173:124-125 (S124,P291), **ISI, impact factor 5.763/2021**

Buda VO, Prelipcean A, Andor M, Cristescu C, Suciu M, Suciu L, Mabda MC, Voicu M, Danciu C, Ledeti I, Petrescu L. Excessive prescription of NSAIDs and theophylline in primary care setting of Romanian elderly population. *Atherosclerosis*. 2021; 331:E270 **ISI, impact factor 6.847/2021**

Buda VO, Dalleur O, Prelipcean A, Man DE, Cretu O, Andor M, Danciu C, Ledeti I, Petrescu L. Misuse of drugs in Romanian elderly population. *Atherosclerosis*. 2021; 331:E269-270 **ISI, impact factor 6.847/2021**

Buda VO, Andor M, Tomescu MC, Cristescu C, Cretu O, Voicu M, Suciu L, Mabda MC, Danciu C, Ledeti I, Petrescu L. Decreased sEng plasma levels in hypertensive patients under chronic treatment with candesartan cilexetil. *Atherosclerosis*. 2020; 315:e260,

<https://doi.org/10.1016/j.atherosclerosis.2020.10.818>, ISI, impact factor **3.919/2019**

Buda VO, Dalleur O, Prelipcean A, Buda S, Andor M, Baibata DE, Dohou A, Petrescu L, Cristescu C. Statins and beta blockers – the most frequently encountered potential prescribing omissions in rural Romanian elderly population. *Atherosclerosis*.2020; 315:e236-e237, <https://doi.org/10.1016/j.atherosclerosis.2020.10.745>, ISI, impact factor **3.919/2019**

Buda V, Andor M, Tomescu MC, Cristescu C, Voicu M, Citu I, Cochera F, Gheorghiu CM, Borcan LC, Glarou ZMA, Tuduce P, Pascu F, Mavrea A, Voicu A, Petrescu L. ACE inhibitors and ARBs decrease more powerful the PTX-3 plasma levels of hypertensive patients with endothelial dysfunction compared with other anti-hypertensive drugs, in a chronic treatment. *European Heart Journal*, Volume 38, Issue suppl_1, 1 August 2017, ehx502.P2637, <https://doi.org/10.1093/eurheartj/ehx502.P2637> ABSTRACT publicat ISI, **factor de impact 23.425/2017**

Buda V, Andor M, Cristescu C, Proks CM, Suci L, Petrescu L, Andrica FM, Tuduce P, Pop D, Muntean C, Daraban A, Borcan LC, Daneasa D, Tomescu MC. The influence of perindopril on endoglin plasma levels compared with other antihypertensive drugs, in a chronic treatment. *European Heart Journal*, Volume 38, Issue suppl_1, 1 August 2017, ehx502.P2633, <https://doi.org/10.1093/eurheartj/ehx502.P2633> ABSTRACT publicat ISI, **factor de impact 23.425/2017**

Buda V, Andor M, Cristescu C, Voicu M, Suci L, Suci M, Proks CM, Muntean C, Munteanu M, Tuduce P, But AR, Udrescu L, Baibata DM, Pop D, Tomescu MC. TSP-1 plasma levels in hypertensive patients with endothelial dysfunction after one year of treatment with ace inhibitors. *Atherosclerosis*. 2017; 263:e139-e140, doi: <https://doi.org/10.1016/j.atherosclerosis.2017.06.445> ABSTRACT publicat ISI, **factor de impact 4.467/2017**